Ajooni Biotech growth ratios

·UnclassifiedChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendFY26Mar 2026FY25Mar 2025FY24Mar 2024FY22 and earlierAlpha Plus
+59.0%+43.2%+7.6%
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
+69.6%+65.1%−19.2%
+56.1%+90.8%−22.8%
+28.2%+56.0%+92.2%
+25.0%−20.0%−87.1%
+26.6%+100.0%−19.1%
+3.5%+106.2%—
+67.7%−348.8%+29.2%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

AJOONI₹2.93

Ajooni Biotech Limited

· Unclassified
₹ CrorePeersTOUCHWOODRKECRAJMETBANKAAAKASHGANGAFORGEGLOBEAGROPHOSMcap ₹50.5 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Revenue Growth—+7.6+43.2+59.0—
EBITDA Growth—-19.2+65.1+69.6—
EBIT Growth—-22.8+90.8+56.1—
Net Income Growth—+92.2+56.0+28.2—
EPS Growth—-87.1-20.0+25.0—
Total Assets Growth—-19.1+100.0+26.6—
Total Equity Growth——+106.2+3.5—
Cash from Operations Growth—+29.2-348.8+67.7—
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.